What is it about?
Apixaban is a direct oral anticoagulant used in non-vavular atrial fibrillation to prevent thromboembolic events such as ischaemic stroke. This review summaries the pivotal studies that were involved in apixaban being licensed for use, and also critically evaluates the new real world evidence that is emerging and specifically analyses patient outcomes such as its effectiveness in stroke prophylaxis and its impact on bleeding complications, whilst taking into consideration its cost effectiveness when compared to other DOACs and warfarin.
Featured Image
Why is it important?
This paper demonstrates the overall benefits of apixaban when compared to its counterparts, and provides information on future perspectives. Therefore it may aid clinicians decisions when deciding between which DOAC is most suitable for their patient.
Perspectives
This article provides an unbiased evaluation of the use of apixaban in non-vavular atrial fibrillation and provides clinicians with a comprehensive summary of the evidence available to justify its use in these patients.
Adam Ioannou
Read the Original
This page is a summary of: Non-valvular atrial fibrillation: impact of apixaban on patient outcomes, Patient Related Outcome Measures, November 2017, Dove Medical Press,
DOI: 10.2147/prom.s117549.
You can read the full text:
Contributors
The following have contributed to this page
